BioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...

The Roctavian program was originally acquired from University College London and appears to have limited commercial potential due to ongoing reimbursement issues in the US and EU. BioMarin has ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), a pharmaceutical company with a market capitalization of $13.15 billion, announced on Monday the appointment of Timothy P. Walbert to its ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16. ...